

ECNP 2026 Preview – Clinical and AI / ML



LucidQuest Intelligence
Accelerate your success



39TH ECNP CONGRESS
10-13 Oct. 2026 | Munich, Germany



ECNP 2026 Preview – Table of Contents

• <u>New Trends in Psychiatric Treatment Strategy At ECNP'26</u>	3-5
• <u>Key Sessions To Watch</u>	6-7
• <u>Industry-sponsored Sessions & Focus Areas At ECNP 2026</u>	8-15
• <u>Competitive Landscape At a Glance at ECNP 2026</u>	9-10
• <u>Key Industry-sponsored Sessions At ECNP 2026</u>	11-15
• <u>New Entrants</u>	16
• <u>AI/ML Trends & Strategic Watchpoints At ECNP 2026</u>	17-19
• <u>AI / Digital Health Angle At ECNP 2026</u>	18-19
• <u>What We're Watching For Post-congress</u>	20
• <u>Get In Touch With LucidQuest</u>	21



- **Schizophrenia competition is expanding across novel mechanisms and earlier, longer-acting treatment**

- ECNP 2026 will bring new data on ML-007C-MA M1/M4 muscarinic agonism and CPL'36 PDE10A inhibition, alongside sessions examining longer-acting injectable antipsychotic strategies. The competitive question will be whether differentiation increasingly comes from novel pharmacology, longer-acting formulations or a combination of both



- **LAIs are being evaluated earlier in the schizophrenia treatment pathway**

- Sessions will examine early LAI intervention, initiation following acute exacerbation, longer treatment intervals, treatment transitions and patient preferences. The key question will be whether earlier initiation and less frequent dosing broaden the role of LAIs beyond later-stage schizophrenia management





- **MDD and TRD competition is widening across NMDA, vasopressin and psychedelic approaches**

- New data for blixeprodil/GM-1020, nelivaptan/BH-200, lysergide and intranasal mebufotenin will sit alongside sessions examining rapid-acting antidepressant approaches. The key question will be whether these approaches separate on speed of action, durability, treatment burden or pharmacological mechanism



- **Precision psychiatry is moving closer to treatment-level decision making**

- Presentations will examine AI-based antidepressant selection, multimodal prediction of lithium response and α 2A-adrenergic receptor agonism in a cognitive depression biotype. The key question will be whether predictive models and defined patient characteristics support more targeted selection of treatments for specific patient groups





- **Digital psychiatry is expanding from episode prediction to active treatment support**

- ECNP 2026 will feature digital phenotyping for prediction of affective episodes, digital therapeutics for depressive disorder and the hiFoon digital companion for adults with ADHD. The question will be whether digital tools establish distinct roles across prediction, monitoring, treatment support and therapeutic intervention.



- **Metabolic safety and treatment practicality are becoming stronger differentiators**

- Sessions will address metabolic risk, cardiovascular and metabolic safety, injection-site tolerability, dosing and treatment switching. The question will be whether safety, tolerability, dosing burden and treatment management become more important differentiators as newer psychiatric therapies expand



Key Sessions To Watch (1/2)

Date	Session Title (short)	Type	Author / Institution	Why Watch
10 Oct 2026	Minocycline and memory reconsolidation: MEMOCYCLINE	Breaking Hot Topic Symposium	Boris B. Quednow	Will provide the first findings from MEMOCYCLINE, examining minocycline-based memory reconsolidation as an approach to intrusive memories across diagnoses..
11 Oct 2026	Multimodal prediction of lithium response: R-LiNK	Symposium	Frank Bellivier	Will examine whether multimodal prediction can help identify lithium response in bipolar I disorder, a central question for more targeted treatment selection.
11 Oct 2026	Digital phenotyping: bipolar vs unipolar disorder	Symposium	Maria Faurholt-Jepsen	Machine-learning models will examine digital phenotyping for classification of bipolar versus unipolar disorder.
11 Oct 2026	α 2A-adrenergic agonism in a cognitive depression biotype	Mini Symposium	Leanne Williams	The study will examine α 2A-adrenergic receptor agonism as treatment for a cognitive biotype of depression.
11 Oct 2026	Nelivaptan BH-200: Phase 2 OLIVE trial	Mini Symposium	Daniel Gehrlach	Will provide a Phase 2 readout for nelivaptan/BH-200, bringing vasopressin 1B antagonism into the MDD treatment landscape.
12 Oct 2026	Cannabidiol vs risperidone in cannabis-related psychosis	Novel Therapies Symposium	Lone Baandrup	Will provide a randomized double-blind direct comparison of cannabidiol and risperidone monotherapy in cannabis-related psychosis.



Key Sessions To Watch (2/2)

Date	Session Title (short)	Type	Author / Institution	Why Watch
12 Oct 2026	Blixeprodil GM-1020 in major depression	Novel Therapies Symposium	Daniel Umbricht	Will provide a randomized placebo-controlled efficacy readout for blixeprodil/GM-1020, an oral NMDA receptor antagonist, in major depression.
12 Oct 2026	CPL'36 PDE10A inhibition in schizophrenia	Novel Therapies Symposium	Mikołaj Matłoka	Will present Phase 2 results for CPL'36, focusing on PDE10A inhibition and positive and negative symptoms in schizophrenia.
12 Oct 2026	ML-007C-MA muscarinic agonism in schizophrenia	Novel Therapies Symposium	Andy Czysz	Will provide Phase 2 ZEPHYR results for ML-007C-MA, adding another clinical readout for muscarinic agonism in schizophrenia.
12 Oct 2026	Phase 3 lysergide in MDD and GAD	Novel Therapies Symposium	Daniel R. Karlin	Will provide Phase 3 data for lysergide across both MDD and GAD, extending the programme across two major affective and anxiety indications.

Industry-Sponsored Sessions & Focus Areas – ECNP 2026





ECNP 2026– Competitive Landscape at a Glance (1/2)

Name	Sessions	Companies / Assets	Why It Matters
Schizophrenia LAI treatment strategy	Multiple	Risperidone ISM, TV-44749, longer-acting injectable antipsychotics	Earlier initiation, longer treatment intervals, switching and patient preferences will test how the role of LAIs evolves across different stages of schizophrenia care
Novel schizophrenia pharmacology	Multiple	ML-007C-MA / M1-M4 agonism, CPL'36 / PDE10A inhibition, muscarinic modulation	New mechanisms will provide a distinct route to differentiation beyond formulation and delivery innovation in schizophrenia
Emerging MDD and TRD mechanisms	Multiple	Blixeprodil/GM-1020, nelivaptan/BH-200	NMDA receptor and vasopressin 1B approaches will broaden the mechanistic landscape in depression and treatment-resistant disease
Psychedelic and rapid-acting antidepressant approaches	Multiple	Mebufotenin / 5-MeO-DMT, lysergide, rapid-acting antidepressant approaches	These sessions will sharpen questions around speed of response, durability and treatment burden in difficult-to-treat depression
Bipolar disorder treatment prediction	Multiple	R-LiNK / lithium-response prediction, digital phenotyping	Prediction of lithium response and digital differentiation of bipolar versus unipolar illness will bring treatment matching and diagnostic refinement into closer focus



ECNP 2026– Competitive Landscape at a Glance (2/2)

Name	Sessions	Companies / Assets	Why It Matters
Digital therapeutics and digital companions	Multiple	Digital therapeutics for depressive disorder, hiFoon for ADHD	Digital interventions will extend beyond monitoring toward treatment support and direct therapeutic use.
Safety, metabolic risk and treatment management	Multiple	Xanomeline/trospium, TV-44749, psychiatric medications	Cardiovascular and metabolic safety, injection-site tolerability, dosing and switching will remain important practical considerations alongside therapeutic innovation.



Key Industry-Sponsored Sessions at ECNP 2026 (1/5)



• **Johnson & Johnson:**

- Focus Areas: Schizophrenia, MDD & Treatment-Resistant Depression
- Johnson & Johnson will focus on earlier and more tailored schizophrenia care, including first-episode management, long-acting treatment and functional outcomes. A separate MDD/TRD symposium will examine real-world evidence, practical treatment choice and patient-centred outcomes



• **GH Research:**

- Focus Areas: Treatment-Resistant Depression & Rapid-Acting Antidepressants
- GH Research will focus on rapid-acting antidepressant approaches in TRD, including clinical outcomes, remission, durability of treatment effect and considerations for use in clinical practice



Key Industry-Sponsored Sessions at ECNP 2026 (2/5)



• Bristol Myers Squibb:

- Focus Areas: Muscarinic Modulation, Schizophrenia, Bipolar Disorder & Alzheimer's Disease
- Bristol Myers Squibb will focus on muscarinic agonism across neurological and psychiatric illnesses, alongside discussion of the evolving treatment landscapes in schizophrenia, bipolar disorder and Alzheimer's disease



• Viatris:

- Focus Areas: Major Depressive Disorder, Generalised Anxiety Disorder & Real-World Evidence
- Viatris will focus on real-world treatment effectiveness and persistence in MDD, together with functioning and everyday disease impact in patients living with GAD



Key Industry-Sponsored Sessions at ECNP 2026 (3/5)



• **Teva Pharmaceuticals:**

- Focus Areas: Schizophrenia, Early LAI Intervention & Personalised Antipsychotic Treatment
- Teva will focus on the timing of LAI intervention in schizophrenia, therapeutic trade-offs in personalised antipsychotic treatment and lessons from contemporary LAI approaches. The symposium will also address how emerging treatment strategies could be implemented in clinical practice



• **Otsuka Pharmaceutical Europe:**

- Focus Areas: Depressive Disorder, Digital Therapeutics & Neuroplasticity
- Otsuka will focus on leveraging neuroplasticity through digital therapeutics for the treatment of depressive disorder, bringing digital intervention into the broader treatment discussion



Key Industry-Sponsored Sessions at ECNP 2026 (4/5)



- **AtaiBeckley:**

- Focus Areas: Treatment-Resistant Depression, Mebufotenin & Rapid-Acting Therapies
- AtaiBeckley will focus on rapid, durable and lower-burden approaches in TRD, including intranasal mebufotenin (5-MeO-DMT), efficacy, durability and safety findings, and considerations for scalable clinical adoption.



- **H. Lundbeck:**

- Focus Areas: Major Depressive Disorder, AI-Based Treatment Selection & Schizophrenia LAIs
- Lundbeck will focus on personalising antidepressant treatment in MDD through AI-based prediction models and patterns of treatment response, alongside a separate schizophrenia symposium on longer-acting injectable antipsychotics, functional recovery, patient preferences and real-world treatment transitions.

Key Industry-Sponsored Sessions at ECNP 2026 (5/5)

- **Angelini Pharma:**

- Focus Areas: Depression, Trazodone & Personalised Treatment
- Angelini will focus on implementing personalised use of trazodone across European clinical practice, moving from consensus-based recommendations toward practical treatment application

- **ROVI:**

- Focus Areas: Acute Schizophrenia, LAIs & Risperidone ISM
- ROVI will focus on unmet needs in acute schizophrenia and early initiation of Risperidone ISM following acute exacerbation, examining how LAI treatment may fit alongside acute symptom control.



New Entrants

Asset / Company	2026 Presence
Nelivaptan	Results of the phase 2 OLIVE trial testing the vasopressin 1b antagonist nelivaptan (BH-200) in major depressive disorder
NH102	Efficacy and safety of NH102 in major depressive disorder: a randomised, phase 2 proof-of-concept clinical trial
SYT-510	Phase 1 studies assessing safety, tolerability, pharmacokinetics and pharmacodynamics of SYT-510, a first-in-class selective endocannabinoid reuptake inhibitor in healthy volunteers
DT-101	DT-101, an α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor positive allosteric modulator, gave target-relevant magnetoencephalographic responses in healthy adults in first in human trial
HS-10380	HS-10380 in patients with schizophrenia: a phase 2b randomised placebo- and active-controlled trial
MT1988	Exploring changes in cognitive, clinical, biological and digital measures after 8 weeks dosing MT1988 in participants at clinical-high-risk for psychosis
MT1980	MT1980: translating anti-inflammatory and metabolic mechanisms into new treatment opportunities for schizophrenia



AI/ML Trends & Strategic Watchpoints at ECNP 2026





AI / Digital Health Angle at ECNP 2026 (1/2)

- **AI and digital-health presentations at ECNP 2026 will focus on treatment selection, response prediction, digital phenotyping, multimodal AI and therapeutic intervention. Sessions on AI-based antidepressant selection, multimodal prediction of lithium response and smartphone-based prediction of emerging affective episodes will examine how digital approaches may support more targeted treatment decisions and identification of clinical change**
- **The programme will also extend beyond prediction through digital therapeutics for depressive disorder, the hiFoon digital companion for adults with ADHD, and virtual reality in youth mental health. A separate AI symposium will cover multimodal markers for clinical outcome stratification, generative AI for symptom extraction, algorithmic fairness and speech-based multimodal AI inference**
- **Key sessions include:**
 - AI-based prediction models to support antidepressant treatment selection
 - Toward multimodal prediction of lithium response in bipolar I disorder: the R-LiNK programme
 - Speech, digital phenotyping, and artificial intelligence in understanding and predicting trajectories and upcoming episodes in affective disorders



AI / Digital Health Angle at ECNP 2026 (2/2)

- Smartphone-based digital phenotyping to predict emerging affective episodes in bipolar patients
- Precision psychiatry through digital phenotyping in major depressive disorder
- How can artificial intelligence transform mental health research?
- Digital therapeutics for the treatment of depressive disorder
- hiFoon: a digital companion for emotion regulation in adults with ADHD
- Virtual reality in youth mental health: evidence, applications and future directions
- **Sessions suggest AI and digital tools are increasingly being used to improve:**
 - Antidepressant treatment selection
 - Prediction of lithium response in bipolar disorder
 - Prediction of emerging affective episodes
 - Digital phenotyping in major depressive disorder
 - Clinical outcome stratification using multimodal markers
 - Symptom extraction and assessment using generative AI
 - Digital therapeutic intervention in depressive disorder
 - Emotion-regulation support in adults with ADHD
 - Assessment and intervention approaches in youth mental health using virtual reality



What We're Watching for Post-ECNP 2026

- Whether ML-007C-MA and CPL'36 provide clearer evidence on the potential roles of M1/M4 muscarinic agonism and PDE10A inhibition in schizophrenia.
- Whether blixeprodil/GM-1020, nelivaptan/BH-200, lysergide and intranasal mebufotenin add meaningful evidence on emerging treatment approaches in MDD and TRD, particularly around efficacy, durability, rapid action or treatment burden where these are addressed in the presentations
- Whether sessions on early LAI intervention, initiation following acute exacerbation and longer-acting injectable treatment clarify how LAIs may be used across different stages of the schizophrenia treatment pathway
- Whether AI-based antidepressant selection, multimodal lithium-response prediction and digital phenotyping provide stronger support for more targeted treatment selection, response prediction and patient stratification.
- Whether presentations on metabolic risk, cardiovascular and metabolic safety, injection-site tolerability, dosing and switching clarify how safety and treatment management may influence the use of newer psychiatric therapies

Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM